Complicated Is A Good Thing

Linda Huguelet |

After finishing two full days of watching abstracts and education sessions about multiple myeloma at the American Society of Hematology Conference (ASH), my head is spinning from the number of new combinations, therapies, and therapy targets. All of this is excellent news for us, but this makes treatment decisions much more complicated. This diagram presented by Dr. […]

The Prom Queen

John DeFlice |

“Bispecifics are the prom queens of ASH”—Tom Martin, M.D. Attending the virtual iteration of ASH has been a unique experience, in that I’ve had the opportunity to see many of the leading international myeloma experts all from the comfort of own home. One of the silver linings of a virtual symposium is that I have […]

It’s All About the Antibodies!

Cynthia Chmielewski |

The antibodies are front and center during the 2020 American Society of Hematology’s Annual Meeting.  I thought this would be a good time to review the mechanism of action (how they work) of each type of antibody. The first antibodies to make it to the myeloma scene were the monoclonal antibodies. (mAbs) Monoclonal antibodies in […]

Virtual ASH 2020: Don’t Stand So Close To Me

Michael Tuohy |

It’s the year 2020 which is a notable year for reasons beside being a global pandemic. For me, 2020 marks my 20th year of survival with multiple myeloma. I am deeply grateful for all the research that has taken place and hopeful for the future of myeloma, all while waiting for a cure. In 2000, […]

The Clock Is Ticking

John DeFlice |

“You have to cherish things in a different way when you know the clock is ticking…”—Chadwick Boseman I recently celebrated the ten-year anniversary of my multiple myeloma diagnosis. I remember racing to the radiology unit at 8 a.m. to review the results of my MRI. I had been on call since 7 a.m. that morning and […]